<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881501</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC009</org_study_id>
    <nct_id>NCT03881501</nct_id>
  </id_info>
  <brief_title>Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma</brief_title>
  <official_title>A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With Sintilimab Injection Plus Endostar in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a a single arm, observational clinical trial to evaluate the efficacy and safety of&#xD;
      combination treatment with sintilimab injection plus endostar in untreated locally advanced&#xD;
      or metastatic hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the first line treatment with untreated locally advanced or metastatic hepatocellular&#xD;
      carcinoma, sintilimab injection plus endostar might be one of the treatment choices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The rate of participants that achieve either a complete response (CR) or a partial response (PR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall survival is defined as time from the start of treatment until death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time between the first recorded and objective remission to the first onset of disease progression or all-cause death (whichever happens first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by number and grade of adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Summary adverse events according to NCI-CTCAE 4.03</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to comply with the study plans in this protocol and sign the informed&#xD;
             consent;&#xD;
&#xD;
          2. Age of 18-75 years;&#xD;
&#xD;
          3. Cytological or histological diagnosis of untreated locally advanced or metastatic&#xD;
             hepatocellular carcinoma;&#xD;
&#xD;
          4. Diseases are not suitable for radical surgery and/or local treatment, or disease&#xD;
             progression occurs after surgery and/or local treatment;&#xD;
&#xD;
          5. At least one measurable lesion as defined by RECIST 1.1 criteria and untreated lesion;&#xD;
&#xD;
          6. Patients who have received previous local treatment (e.g., radiofrequency ablation,&#xD;
             ethanol or acetic acid injection, cryoablation, high intensity focused ultrasound,&#xD;
             transcatheter arterial chemoembolization, transcatheter arterial embolization, etc.)&#xD;
             are eligible to participate in the study if the target lesion has not received local&#xD;
             treatment before, or if the target lesion within the scope of local treatment has&#xD;
             subsequently developed on the basis of RECIST v1.1;&#xD;
&#xD;
          7. ECOG performance status of 0-1;&#xD;
&#xD;
          8. Child-Pugh A;&#xD;
&#xD;
          9. Bone marrow function: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT)&#xD;
             ≥75×109 /L, hemoglobin(HB) ≥90 g/L;&#xD;
&#xD;
         10. alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤5 x upper limit&#xD;
             of normal range (ULN);total bilirubin (TBIL)≤3 x upper limit of normal range&#xD;
             (ULN);Creatinine(Cr)≤1.5 x upper limit of normal range(ULN);Serum albumin (&gt; 28 g/L)&#xD;
             (2.8 g/dL);Patients not receiving anticoagulation therapy: INR or aPTT &lt; 2&#xD;
             *ULN;Urinary cellulose test paper results Proteinuria &lt; 2 (7 days before the start of&#xD;
             treatment);Patients with baseline cellulose test paper urine test results (&gt; 2&#xD;
             proteinuria) should collect 24-hour urine, and then must confirm that the 24-hour&#xD;
             urinary protein content is less than 1 g;&#xD;
&#xD;
         11. HIV test results were negative at screening;&#xD;
&#xD;
         12. Records of virological status of hepatitis, confirmed by serological tests of HBV and&#xD;
             HCV;&#xD;
&#xD;
         13. Patients with active hepatitis B virus (HBV) infection:HBV DNA &lt; 500 IU/mL was&#xD;
             obtained within 28 days before the start of the study, and received at least 14 days&#xD;
             of anti-HBV treatment (based on local standard treatment, such as entecavir) prior to&#xD;
             the study, and was willing to continue treatment during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systemic HCC treatment has been received in the past;&#xD;
&#xD;
          2. History of primary immunodeficiency is known;&#xD;
&#xD;
          3. It is known to have active tuberculosis;&#xD;
&#xD;
          4. History of allogeneic organ transplantation and hematopoietic stem cell&#xD;
             transplantation is known;&#xD;
&#xD;
          5. It is known that there is a history of human immunodeficiency virus (HIV) infection&#xD;
             (that is, HIV antibody positive);&#xD;
&#xD;
          6. Severe allergic/allergic reactions to humanized antibodies or fusion proteins were&#xD;
             observed;&#xD;
&#xD;
          7. It is known to have hypersensitivity to any component contained in Endor preparations;&#xD;
&#xD;
          8. Initial serious heart disease patients include congestive heart failure,&#xD;
             uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction,&#xD;
             severe valvular disease and refractory hypertension;&#xD;
&#xD;
          9. History of PIA meningitis;&#xD;
&#xD;
         10. Major cardiovascular diseases (e.g. New York Heart Association Grade II or more&#xD;
             serious heart disease, myocardial infarction or cerebrovascular accident), unstable&#xD;
             arrhythmia or unstable angina pectoris, occurred within three months before the start&#xD;
             of treatment;&#xD;
&#xD;
         11. Major surgical treatments (except diagnosis) were received within 4 weeks before the&#xD;
             start of the study, or major surgical treatments were expected during the study&#xD;
             period;&#xD;
&#xD;
         12. Other malignant tumors were diagnosed within 5 years before the first administration.&#xD;
             Exceptions included radical basal cell carcinoma, squamous cell carcinoma, adequately&#xD;
             treated cervical cancer in situ, and localized prostate cancer;&#xD;
&#xD;
         13. Active infections requiring systemic treatment;&#xD;
&#xD;
         14. Fiberboard HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC are known;&#xD;
&#xD;
         15. Moderate or severe ascites;&#xD;
&#xD;
         16. History of hepatic encephalopathy;&#xD;
&#xD;
         17. Patients with a history of HCV infection but negative results of HCV RNA PCR may&#xD;
             consider that they are not infected with HCV;&#xD;
&#xD;
         18. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy is&#xD;
             being administered within 7 days prior to the diagnosis of immunodeficiency or the&#xD;
             study's first administration; physiological doses of glucocorticoid (&lt;10mg/day&#xD;
             prednisone or equivalent) are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <phone>8627-83663406</phone>
    <email>xlyuan1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanmei Zou, MD,PhD</last_name>
    <phone>8627-83663406</phone>
    <email>zouyanmei0101@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, MD,PHD</last_name>
      <phone>8627-83663406</phone>
      <email>xlyuan1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanmei Zou, MD,PHD</last_name>
      <phone>8627-83663406</phone>
      <email>zouyanmei0101@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 16, 2019</last_update_submitted>
  <last_update_submitted_qc>March 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Head of the cancer center</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sintilimab Injection</keyword>
  <keyword>Endostar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

